Inactive Instrument

Audentes Therapeutics, Inc.

US05070R1041

Biotechnology & Medical Research

Certain options of Audentes Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2017.

January 15, 2017

Certain options of Audentes Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2017. These options will be under lockup for 180 days starting from 20-JUL-2016 to 16-JAN-2017.

Latest news about Audentes Therapeutics, Inc.

Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	03-14	CI
Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	22-11-07	CI
Taysha Gene Therapies, Inc. announced that it expects to receive $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	22-10-20	CI
Audentes Therapeutics, Inc. Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy	20-12-24	CI
Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy	20-08-21	CI
Audentes Therapeutics, Inc. Appoints Julie Person as Senior Vice President, Human Resources	20-04-21	CI
Audentes Therapeutics, Inc. Plans to Build New Gene Therapy Manufacturing Facility in Sanford, North Carolina	20-02-18	CI
Audentes Therapeutics, Inc. Announces Management Changes	20-01-15	CI
Audentes Therapeutics, Inc. Approves a Change in the Company’s Fiscal Year to End on March 31	20-01-15	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P TMI Index	20-01-15	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Biotechnology Select Industry Index	20-01-15	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Global BMI Index	20-01-15	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from NASDAQ Composite Index	20-01-14	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from NASDAQ Biotechnology Index	20-01-14	CI
Astellas US Holding, Inc. completed the acquisition of Audentes Therapeutics, Inc..	20-01-13	CI
Takeda Pharmaceutical : Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million	19-12-26	RE
Roche : dives deeper into gene therapy with $1.15 billion Sarepta licensing deal	19-12-23	RE
Japanese shares slip on concerns of longer trade war	19-12-03	RE
Wall Street falls as trade hopes wane	19-12-03	RE
Astellas Pharma : Japan's Astellas to buy Audentes for $3 billion in high-priced gene therapy bet	19-12-03	RE
Nikkei slips on fresh global trade concerns, weak U.S. data	19-12-03	RE
Astellas US Holding, Inc. entered into a definitive agreement to acquire Audentes Therapeutics, Inc. for $2.8 billion.	19-12-01	CI
Audentes Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-07	CI
Transcript : Audentes Therapeutics, Inc., Q3 2019 Earnings Call, Nov 07, 2019	19-11-07
Audentes Therapeutics Announces New Positive Data from ASPIRO	19-10-09	CI

Chart Audentes Therapeutics, Inc.

Duration

Period

More charts

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs

Audentes Therapeutics, Inc.

Equities

US05070R1041

Biotechnology & Medical Research

Certain options of Audentes Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2017.

Latest news about Audentes Therapeutics, Inc.

Chart Audentes Therapeutics, Inc.

Company Profile

Sector Bio Therapeutic Drugs